Objective To investigate short-term efficacy and safety of intensive statin in acute coronary syndrome (ACS) after percutaneous coronary intervention. Methods 410 cases with ACS in our hospital from May 2014 to May 2016 were selected in this study. All of them were treated with percutaneous coronary artery interventional therapy, and intensive lipid-lowering therapy in patients with the daily 40mg, giving atorvastatin oral treatment, treatment of this group of patients before treatment and the changes of blood lipid after 1 month to observe and evaluate the clinical efficacy and safety of intensive statin therapy. Results After 1 month treatment of intensive statin, this group of 410 patients with TC,TG,LDL-C and other clinical indicators before treatment were significantly decreased compared with 1 month before treatment with statistical significance (P<0.05),and the level of Cr had little difference with no statistical significance(P>0.05). The standard rate blood lipid was 96.59%. Side effects were occurred in 21 cases among 410 patients (7.56%). Conclusion Intensive statin therapy in ACS percutaneous coronary intervention in patients with good effect, administered to a patient after taking a lot of early intervention therapy atorvastatin can significantly lower their blood lipid levels, improve liver and kidney function, and low incidence of adverse reactions, is safe and effective, worthy of promotion.